FHIR IG analytics| Package | flute.requirements |
| Resource Type | Requirements |
| Id | Requirements-F-PIL-2.json |
| FHIR Version | R5 |
| Source | https://build.fhir.org/ig/hl7-eu/flute-requirements/Requirements-F-PIL-2.html |
| URL | https://flute.com/Requirements/F-PIL-2 |
| Version | 0.1.0 |
| Status | draft |
| Date | 2023-10-25T10:31:30.239Z |
| Name | F_PIL_2 |
| Title | F-PIL-2 |
| Authority | hl7 |
| Description | Cohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE. |
| Purpose | FLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners. |
| Copyright | HL7 Europe |
| Copyright Label | Federated Learning and mUlti-party computation Techniques for prostatE cancer |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
ID: F-PIL-2
Publisher: HL7 Europe
| Contact Name | Contact Points |
|---|---|
| HL7 Europe |
Description:
Cohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.
Purpose:
FLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners.
Copyright Label: Federated Learning and mUlti-party computation Techniques for prostatE cancer
Statements:
ID: F-PIL-2
Label: Cohorts SHALL consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.
Sources:
- HL7 Europe
Conformance Requirement SHALLconsist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE
{
"resourceType": "Requirements",
"id": "F-PIL-2",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"url": "https://flute.com/Requirements/F-PIL-2",
"version": "0.1.0",
"name": "F_PIL_2",
"title": "F-PIL-2",
"status": "draft",
"date": "2023-10-25T10:31:30.239Z",
"publisher": "HL7 Europe",
"contact": [
{
"name": "HL7 Europe",
"telecom": [
{
"system": "url",
"value": "https://www.hl7.eu"
}
]
}
],
"description": "Cohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.",
"purpose": "FLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners.",
"copyright": "HL7 Europe",
"copyrightLabel": "Federated Learning and mUlti-party computation Techniques for prostatE cancer",
"statement": [
{
"key": "F-PIL-2",
"label": "Cohorts SHALL consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.",
"conformance": [
"SHALL"
],
"requirement": "consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE",
"source": [
{
"display": "HL7 Europe"
}
]
}
]
}